Impel Pharmaceuticals Announces First Patient Dosed in Phase IIa Study Evaluating INP105 to Treat Acute Agitation in Adolescents with Autism Spectrum Disorder (ASD)

Impel Pharmaceuticals announced the first subject has been dosed in a Phase IIa proof-of-concept study of INP105, nasal olanzapine, a widely used atypical, second-generation antipsychotic.